



## Complete Summary

---

### GUIDELINE TITLE

Recommended immunization schedules for children and adolescents: United States, 2007.

### BIBLIOGRAPHIC SOURCE(S)

American Academy of Pediatrics Committee on Infectious Diseases. Recommended immunization schedules for children and adolescents--United States, 2007. *Pediatrics* 2007 Jan;119(1):207-8, 3 p following 208. [2 references] [PubMed](#)

Centers for Disease Control and Prevention. Recommended immunization schedules for persons aged 0-18 years - United States, 2007. *MMWR Recomm Rep* 2007 Jan 5;55(51-52):Q1-4. [6 references]

### GUIDELINE STATUS

This is the current release of the guideline.

This guideline updates previously published versions: American Academy of Pediatrics, Committee on Infectious Disease. Recommended childhood and adolescent immunization schedule--United States, 2006. *Pediatrics* 2006 Jan;117(1):239-40.

Centers for Disease Control and Prevention (CDC). Recommended childhood and adolescent immunization schedule -- United States, 2006. *MMWR Morb Mortal Wkly Rep* 2006 Jan 6;54(51&52):Q1-4.

## \*\* REGULATORY ALERT \*\*

### FDA WARNING/REGULATORY ALERT

**Note from the National Guideline Clearinghouse:** This guideline references a drug(s) for which important revised regulatory and/or warning information has been released.

- [June 15, 2007, RotaTeq \(Rotavirus, Live, Oral, Pentavalent Vaccine\)](#): Changes to the ADVERSE REACTIONS and POST-MARKETING sections of the product's prescribing information. The ADVERSE REACTIONS section was updated to include six cases of Kawasaki disease that were observed during the Phase 3 clinical trial.

## COMPLETE SUMMARY CONTENT

\*\* REGULATORY ALERT \*\*

SCOPE

METHODOLOGY - including Rating Scheme and Cost Analysis

RECOMMENDATIONS

EVIDENCE SUPPORTING THE RECOMMENDATIONS

BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS

QUALIFYING STATEMENTS

IMPLEMENTATION OF THE GUIDELINE

INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT

CATEGORIES

IDENTIFYING INFORMATION AND AVAILABILITY

DISCLAIMER

## SCOPE

### DISEASE/CONDITION(S)

Vaccine-preventable diseases:

- Diphtheria
- Hepatitis A and B
- *Haemophilus influenzae* infection
- Human papillomavirus (HPV) infection
- Influenza
- Measles
- Meningococcal disease
- Mumps
- Pertussis
- Pneumococcal infection
- Rotavirus infection
- Polio
- Rubella
- Tetanus
- Varicella (chickenpox)

### GUIDELINE CATEGORY

Prevention

### CLINICAL SPECIALTY

Family Practice  
Infectious Diseases  
Pediatrics  
Preventive Medicine

### INTENDED USERS

Advanced Practice Nurses  
Health Care Providers  
Nurses  
Physician Assistants  
Physicians  
Public Health Departments

### **GUIDELINE OBJECTIVE(S)**

- To ensure that the recommended childhood and adolescent immunization schedule is current with changes in vaccine formulations
- To reflect revised recommendations for the use of licensed vaccines, including those newly licensed

### **TARGET POPULATION**

Children and adolescents through 18 years residing in the United States

### **INTERVENTIONS AND PRACTICES CONSIDERED**

Immunization with the following vaccines:

1. Diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP/Tdap/Td)
2. *Haemophilus influenzae* type b (Hib) conjugate
3. Hepatitis A and B (HepA and HepB) vaccine
4. Inactivated polio virus (IPV)
5. Influenza vaccine
  - Intramuscular trivalent inactivated influenza vaccine (TIV)
  - Live-attenuated influenza vaccine (LAIV)
6. Measles, mumps and rubella (MMR) vaccine
7. Meningococcal vaccine
  - Meningococcal conjugate vaccine (MCV4)
  - Meningococcal polysaccharide vaccine (MPSV4)
8. Pneumococcus
  - Pneumococcal conjugate vaccine (PCV)
  - Pneumococcal polysaccharide vaccine (PPV)
9. Varicella vaccine
10. Rotavirus vaccine (Rota)
11. Human papillomavirus vaccine

### **MAJOR OUTCOMES CONSIDERED**

Not stated

## **METHODOLOGY**

### **METHODS USED TO COLLECT/SELECT EVIDENCE**

Searches of Electronic Databases

**DESCRIPTION OF METHODS USED TO COLLECT/SELECT THE EVIDENCE**

Not stated

**NUMBER OF SOURCE DOCUMENTS**

Not stated

**METHODS USED TO ASSESS THE QUALITY AND STRENGTH OF THE EVIDENCE**

Not stated

**RATING SCHEME FOR THE STRENGTH OF THE EVIDENCE**

Not applicable

**METHODS USED TO ANALYZE THE EVIDENCE**

Review

**DESCRIPTION OF THE METHODS USED TO ANALYZE THE EVIDENCE**

Not stated

**METHODS USED TO FORMULATE THE RECOMMENDATIONS**

Not stated

**RATING SCHEME FOR THE STRENGTH OF THE RECOMMENDATIONS**

Not applicable

**COST ANALYSIS**

A formal cost analysis was not performed and published cost analyses were not reviewed.

**METHOD OF GUIDELINE VALIDATION**

Peer Review

**DESCRIPTION OF METHOD OF GUIDELINE VALIDATION**

The recommended immunization schedules for persons aged 0 to 18 years and the catch-up immunization schedule for 2007 were approved by the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention, the American Academy of Pediatrics, and the American Academy of Family Physicians.

## RECOMMENDATIONS

### MAJOR RECOMMENDATIONS

**Note from the National Guideline Clearinghouse (NGC):** *The guideline recommendations are presented in the form of tables with footnotes (see below). The changes to the previous childhood and adolescent immunization schedule, published January 2006, are as follows:*

- The new rotavirus vaccine (Rota) is recommended in a 3-dose schedule at ages 2, 4, and 6 months. The first dose should be administered at ages 6 weeks through 12 weeks. With subsequent doses administered at 4 to 10 week intervals. Rotavirus vaccination should not be initiated for infants aged >12 weeks and should not be administered after age 32 weeks.
- The influenza vaccine is now recommended for all children aged 6 to 59 months.
- Varicella vaccine recommendations are updated. The first dose should be administered at age 12 to 15 months, and a newly recommended second dose should be administered at age 4 to 6 years.
- The new human papillomavirus vaccine (HPV) is recommended in a 3-dose schedule with the second and third doses administered 2 and 6 months after the first dose. Routine vaccination with HPV is recommended for females aged 11 to 12 years; the vaccination series can be started in females as young as age 9 years; and a catch-up vaccination is recommended for females aged 13 to 26 years who have not been vaccinated previously or who have not completed the full vaccine series.
- The main change to the format of the schedule is the division of the recommendation into two schedules: one schedule for persons aged 0 to 6 years and another for persons aged 7 to 18 years. Special populations are represented with purple bars; the 11 to 12 years assessment is emphasized with bold, capitalized fonts in the title of that column. Rota, HPV, and varicella vaccines are incorporated in the catch-up immunization schedule.

### Vaccine Information Statements

The National Childhood Vaccine Injury Act requires that health-care providers provide parents or patients with copies of Vaccine Information Statements before administering each dose of the vaccines listed in the schedule. Additional information is available from state health departments and from the Centers for Disease Control and Prevention (CDC) at <http://www.cdc.gov/vaccines/pubs/default.htm>.

Detailed recommendations for using vaccines are available from package inserts, ACIP statements on specific vaccines, and the *2003 Red Book*. ACIP statements for each recommended childhood vaccine are available from CDC at <http://www.cdc.gov/vaccines/recs/acip/default.htm>. In addition, guidance for obtaining and completing a Vaccine Adverse Event Reporting System form is available at <http://www.vaers.hhs.gov> or by telephone, 800-822-7967.

### Recommended Immunization Schedule for Ages 0 to 6 Years – United States, 2007

| Vaccine   | Birth | 1 month | 2 months | 4 months       | 6 months           | 12 months      | 15 months | 18 months | 19 to 23 months | 2 to 3 years | 4 years |
|---|-------|---------|----------|----------------|--------------------|----------------|-----------|-----------|-----------------|--------------|---------|
| <b>Hepatitis B<sup>1</sup></b>                    | HepB  | HepB    |          | See footnote 1 |                    | HepB           |           |           | HepB Series     |              |         |
| <b>Rotavirus<sup>2</sup></b>                      |       |         | Rota     | Rota           | Rota               |                |           |           |                 |              |         |
| <b>Diphtheria, Tetanus, Pertussis<sup>3</sup></b> |       |         | DTaP     | DTaP           | DTaP               |                | DTaP      |           |                 |              |         |
| <b>Haemophilus influenzae type b<sup>4</sup></b>  |       |         | Hib      | Hib            | Hib <sup>4</sup>   | Hib            |           | Hib       |                 |              |         |
| <b>Pneumococcal<sup>5</sup></b>                   |       |         | PCV      | PCV            | PCV                | PCV            |           |           |                 | PCV          | PP      |
| <b>Inactivated Poliovirus</b>                     |       |         | IPV      | IPV            | IPV                |                |           |           |                 |              |         |
| <b>Influenza<sup>6</sup></b>                      |       |         |          |                | Influenza (Yearly) |                |           |           |                 |              |         |
| <b>Measles, Mumps, Rubella<sup>7</sup></b>        |       |         |          |                |                    | MMR            |           |           |                 |              |         |
| <b>Varicella<sup>8</sup></b>                      |       |         |          |                |                    | Varicella      |           |           |                 |              | V       |
| <b>Hepatitis A<sup>9</sup></b>                    |       |         |          |                |                    | HepA (2 doses) |           |           |                 | HepA S       |         |
| <b>Meningococcal<sup>10</sup></b>                 |       |         |          |                |                    |                |           |           |                 |              | MPSV    |

|                                  |                              |                                 |
|----------------------------------|------------------------------|---------------------------------|
| <b>Range of recommended ages</b> | <b>Catch-up immunization</b> | <b>Certain high-risk groups</b> |
|----------------------------------|------------------------------|---------------------------------|

This schedule indicates the recommended ages for routine administration of currently licensed childhood vaccines, as of December 1, 2006, for children aged 0 to 6 years. Additional information is available at <http://www.cdc.gov/vaccines/recs/schedules/child-schedule.htm#printable>. Any dose not administered at the recommended age should be administered at any subsequent visit, when indicated and feasible. Additional vaccines may be licensed and recommended during the year. Licensed combination vaccines may be used whenever any components of the combination are indicated and other components of the vaccine are not contraindicated and if approved by the Food and Drug Administration for that dose of the series. Providers should consult the respective Advisory Committee on Immunization Practices (ACIP) statement for detailed recommendations. Clinically significant adverse events that follow immunization should be reported to the Vaccine Adverse Event Reporting System (VAERS). Guidance about how to obtain and complete a VAERS form is available at <http://www.vaers.hhs.gov> or by telephone, 800-822-7967.

\***Note:** The CDC has updated its recommendations regarding vaccination against meningococcal disease. See the [CDC Web site](#) for details.

1. **Hepatitis B vaccine (HepB).** (Minimum age: birth)

**At birth:**

- Administer monovalent HepB to all newborns prior to hospital discharge.
- If mother is hepatitis B surface antigen (HBsAg)-positive, administer HepB and 0.5 mL of hepatitis B immune globulin (HBIG) within 12 hours of birth.
- If mother's HBsAg status is unknown, administer HepB within 12 hours of birth. Determine the HBsAg status as soon as possible and if HBsAg-positive, administer HBIG (no later than age 1 week).
- If mother is HBsAg-negative, the birth dose can only be delayed with physician's order and mothers' negative HBsAg laboratory report documented in the infant's medical record.

**Following the birth dose:**

- The HepB series should be completed with either monovalent HepB or a combination vaccine containing HepB. The second dose should be administered at age 1 to 2 months. The final dose should be administered at age  $\geq 24$  weeks. Infants born to HBsAg-positive mothers should be tested for HBsAg and antibody to HBsAg after completion of  $\geq 3$  doses in a licensed HepB series, at age 9 to 18 months (generally at the next well-child visit).

**4-month dose of HepB:**

- It is permissible to administer 4 doses of HepB when combination vaccines are given after the birth dose. If monovalent HepB is used for doses after the birth dose, a dose at age 4 months is not needed.

**2. Rotavirus vaccine (Rota).** *(Minimum age: 6 weeks)*

- Administer the first dose between 6 and 12 weeks of age. Do not start the series later than age 12 weeks.
- Administer the final dose in the series by 32 weeks of age. Do not administer a dose later than age 32 weeks.
- There are insufficient data on safety and efficacy outside of these age ranges.

**3. Diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP).** *(Minimum age: 6 weeks)*

- The fourth dose of DTaP may be administered as early as age 12 months, provided 6 months have elapsed since the third dose.
- Administer the final dose in the series at age 4 to 6 years.

**4. Haemophilus influenzae type b conjugate vaccine (Hib).** *(Minimum age: 6 weeks)*

- If PRP-OMP (PedvaxHIB® or ComVax® [Merck]) is administered at ages 2 and 4 months, a dose at age 6 months is not required.
- TriHiBit® (DTaP/Hib) combination products should not be used for primary immunization but can be used as boosters following any Hib vaccine in  $\geq 12$  months olds.

5. **Pneumococcal vaccine.** (*Minimum age: 6 weeks for pneumococcal conjugate vaccine [PCV]; 2 years for pneumococcal polysaccharide vaccine [PPV]*)
- Administer PCV at ages 24 to 59 months in certain high-risk groups. Administer PPV to children aged  $\geq 2$  years in certain high-risk groups. See *MMWR* 2000; 49(RR-9):1-35.\*
- \*Note:** Updated recommendations for the use of PCV7 in children aged 24 to 59 months have been released. Please see the [CDC Web site](#) for details.
6. **Influenza vaccine.** (*Minimum age: 6 months for trivalent inactivated influenza vaccine [TIV]; 5 years for live, attenuated influenza vaccine [LAIV]*)
- All children aged 6 to 59 months and close contacts of all children aged 0 to 59 months are recommended to receive influenza vaccine.
  - Influenza vaccine is recommended annually for children aged  $\geq 59$  months with certain risk factors, healthcare workers, and other persons (including household members) in close contact with persons in groups at high risk. See *MMWR* 2006; 55(RR-10):1-41.
  - For healthy persons aged 5 to 49 years, LAIV may be used as an alternative to TIV.
  - Children receiving TIV should receive 0.25 mL if aged 6 to 35 months or 0.5 mL if aged  $\geq 3$  years.
  - Children aged  $< 9$  years who are receiving influenza vaccine for the first time should receive 2 doses (separated by  $\geq 4$  weeks for TIV and  $\geq 6$  weeks for LAIV).
7. **Measles, mumps, and rubella vaccine (MMR).** (*Minimum age: 12 months*)
- Administer the second dose of MMR at age 4 to 6 years. MMR may be administered before age 4 to 6 years, provided  $\geq 4$  weeks have elapsed since the first dose and both doses are administered at age  $\geq 12$  months.
8. **Varicella vaccine.** (*Minimum age: 12 months*)
- Administer the second dose of varicella vaccine at age 4 to 6 years. Varicella vaccine may be administered prior to age 4 to 6 years, provided that  $\geq 3$  months have elapsed since the first dose and both doses are administered at age  $\geq 12$  months. If second dose was administered  $\geq 28$  days following the first dose, the second dose does not need to be repeated.
9. **Hepatitis A vaccine (HepA).** (*Minimum age: 12 months*)
- HepA is recommended for all children at 1 year of age (i.e., 12 to 23 months). The 2 doses in the series should be administered at least 6 months apart.
  - Children not fully vaccinated by age 2 years can be vaccinated at subsequent visits.
  - HepA is recommended for certain other groups of children including in areas where vaccination programs target older children. See *MMWR* 2006; 55(RR-7):1-23.
10. **Meningococcal polysaccharide vaccine (MPSV4).** (*Minimum age: 2 years*)

- Administer MPSV4 to children aged 2 to 10 years with terminal complement deficiencies or anatomic or functional asplenia and certain other high risk groups. See *MMWR* 2005;54 (RR-7):1-21.

**Note:** The CDC has updated its recommendations regarding vaccination against meningococcal disease. See the [CDC Web site](#) for details.

**Recommended immunization schedule for persons aged 7 to 18 years -- United States, 2007**

| Vaccine   | 7 to 10 years             | 11 to 12 YEARS       | 13 to 14 years | 15 years          | 16 to 18 years |
|---|---------------------------|----------------------|----------------|-------------------|----------------|
| <b>Tetanus, Diphtheria, Pertussis<sup>1</sup></b> | See footnote 1            | <b>Tdap</b>          | Tdap           |                   |                |
| <b>Human Papillomavirus<sup>2</sup></b>           | See footnote 2            | <b>HPV (3 doses)</b> | HPV Series     |                   |                |
| <b>Meningococcal<sup>3</sup></b>                  |                           | <b>MCV4</b>          |                | MCV4 <sup>3</sup> |                |
|   | MPSV4*                    |                      | MCV4           |                   |                |
| <b>Pneumococcal<sup>4</sup></b>                   | <b>PPV</b>                |                      |                |                   |                |
| <b>Influenza<sup>5</sup></b>                      | <b>Influenza (Yearly)</b> |                      |                |                   |                |
| <b>Hepatitis A<sup>6</sup></b>                    | <b>HepA Series</b>        |                      |                |                   |                |
| <b>Hepatitis B<sup>7</sup></b>                    | <b>HepB Series</b>        |                      |                |                   |                |
| <b>Inactivated Poliovirus<sup>8</sup></b>         | <b>IPV Series</b>         |                      |                |                   |                |
| <b>Measles, Mumps, Rubella<sup>9</sup></b>        | <b>MMR Series</b>         |                      |                |                   |                |
| <b>Varicella<sup>10</sup></b>                     | <b>Varicella Series</b>   |                      |                |                   |                |

|                                  |                              |                                 |
|----------------------------------|------------------------------|---------------------------------|
| <b>Range of recommended ages</b> | <b>Catch-up immunization</b> | <b>Certain high-risk groups</b> |
|----------------------------------|------------------------------|---------------------------------|

This schedule indicates the recommended ages for routine administration of currently licensed childhood vaccines, as of December 1, 2006, for children aged 7 to 18 years. Additional information is available at <http://www.cdc.gov/vaccines/recs/schedules/child-schedule.htm#printable>. Any dose not administered at the recommended age should be administered at any subsequent visit, when indicated and feasible. Additional vaccines may be licensed and recommended during the year. Licensed combination vaccines may be used whenever any components of the combination are indicated and other components of the vaccine are not contraindicated and if approved by the Food and Drug Administration for that dose of the series. Providers should consult the respective ACIP statement for detailed recommendations. Clinically significant adverse events that follow immunization should be reported to the Vaccine Adverse Event Reporting System (VAERS). Guidance about how to obtain and complete a VAERS form is available at <http://www.vaers.hhs.gov> or by telephone, 800-822-7967.

**\*Note:** The CDC has updated its recommendations regarding vaccination against meningococcal disease. See the [CDC Web site](#) for details.

1. **Tetanus and diphtheria toxoids and acellular pertussis vaccine (Tdap).** (*Minimum age: 10 years for BOOSTRIX<sup>®</sup> and 11 years for ADACEL<sup>™</sup>*)
  - Administer at age 11 to 12 years for those who have completed the recommended childhood DTP/DTaP vaccination series and have not received a Td booster dose.
  - Adolescents 13 to 18 years who missed the 11 to 12 year Td/Tdap booster dose should also receive a single dose of Tdap if they have completed the recommended childhood DTP/DTaP vaccination series.
  
2. **Human papillomavirus vaccine (HPV).** (*Minimum age: 9 years*)
  - Administer the first dose of the HPV vaccine series to females at age 11 to 12 years.
  - Administer the second dose 2 months after the first dose and the third dose 6 months after the first dose.
  - Administer the HPV vaccine series to females at age 13 to 18 years if not previously vaccinated.
  
3. **Meningococcal vaccine.** (*Minimum age: 11 years for meningococcal conjugate vaccine [MCV4]; 2 years for meningococcal polysaccharide vaccine [MPSV4]*)
  - Administer MCV4 at age 11 to 12-years and to previously unvaccinated adolescents at high school entry (approximately 15 years of age).
  - Administer MCV4 to previously unvaccinated college freshmen living in dormitories; MPSV4 is an acceptable alternative.
  - Vaccination against invasive meningococcal disease is recommended for children and adolescents aged  $\geq 2$  years with terminal complement deficiencies or anatomic or functional asplenia and certain other high risk groups. See *MMWR* 2005;54 (RR-7):1-21. Use MPSV4 for children aged 2 to 10 years and MCV4 or MPSV4 for older children.
  
- Note:** The CDC has updated its recommendations regarding vaccination against meningococcal disease. See the [CDC Web site](#) for details.
  
4. **Pneumococcal polysaccharide vaccine (PPV).** (*Minimum age: 2 years*)
  - Administer for certain high-risk groups. See *MMWR* 1997;46(RR-08); 1-24 and *MMWR* 2000;49(RR-9):1-35.
  
5. **Influenza vaccine.** (*Minimum age: 6 months for trivalent inactivated influenza vaccine [TIV]; 5 years for live, attenuated influenza vaccine [LAIV]*)
  - Influenza vaccine is recommended annually for persons with certain risk factors, healthcare workers, and other persons (including household members) in close contact with persons in groups at high risk. See *MMWR* 2006; 55(RR-10);1-41.
  - For healthy persons aged 5 to 49 years, LAIV may be used as an alternative to TIV.
  - Children aged <9 years who are receiving influenza vaccine for the first time should receive 2 doses (separated by  $\geq 4$  weeks for TIV and  $\geq 6$  weeks for LAIV).
  
6. **Hepatitis A vaccine (HepA).** (*Minimum age: 12 months*)
  - The 2 doses in the series should be administered at least 6 months apart.

- HepA is recommended for certain other groups of children including in areas where vaccination programs target older children. See *MMWR* 2006;55(RR-7):1-23.

**7. Hepatitis B vaccine (HepB).** (*Minimum age: birth*)

- Administer the 3-dose series to those who were not previously vaccinated.
- A 2-dose series of Recombivax HB® is licensed for 11 to 15 year olds.

**8. Inactivated poliovirus vaccine (IPV).** (*Minimum age: 6 weeks*)

- For children who received an all-IPV or all-oral poliovirus (OPV) series, a fourth dose is not necessary if third dose was administered at age  $\geq 4$  years.
- If both OPV and IPV were administered as part of a series, a total of 4 doses should be given, regardless of the child's current age.

**9. Measles, mumps, and rubella vaccine (MMR).** (*Minimum age: 12 months*)

- If not previously vaccinated, administer 2 doses of MMR during any visit with  $\geq 4$  weeks between the doses.

**10. Varicella vaccine.** (*Minimum age: 12 months*)

- Administer 2 doses of varicella vaccine to persons without evidence of immunity.
- Administer 2 doses of varicella vaccine to persons aged  $\leq 13$  years at least 3 months apart. Do not repeat the second dose, if administered  $\geq 28$  days following the first dose.
- Administer 2 doses of varicella vaccine to persons aged  $\geq 13$  years at least 4 weeks apart.

**Catch-up Immunization Schedule for Persons Aged 4 Months to 18 Years Who Start Late or Who Are  $\geq 1$  Month Behind—United States, 2007**

The tables below give catch-up schedules and minimum intervals between doses for children whose vaccinations have been delayed. A vaccine series does not need to be restarted, regardless of the time that has elapsed between doses. Use the table appropriate for the child's age.

| <b>Catch-up Schedule for Persons Aged 4 Months to 6 Years</b> |                               |                                       |  |                         |                         |
|---|-------------------------------|---------------------------------------|--|-------------------------|-------------------------|
| <b>Vaccine</b>  | <b>Minimum age for Dose 1</b> | <b>Minimum Interval between Doses</b> |  |                         |                         |
|   |                               | <b>Dose 1 to Dose 2</b>               | <b>Dose 2 to Dose 3</b>                    | <b>Dose 3 to Dose 4</b> | <b>Dose 4 to Dose 5</b> |
| <b>Hepatitis B<sup>1</sup></b>                                | Birth                         | 4 weeks                               | 8 weeks<br>(and 16 weeks after first dose) |                         |                         |
| <b>Rotavirus<sup>2</sup></b>                                  | 6 weeks                       | 4 weeks                               | 4 weeks                                    |                         |                         |
| <b>Diphtheria, Tetanus, Pertussis<sup>3</sup></b>             | 6 weeks                       | 4 weeks                               | 4 weeks                                    | 6 months                | 6 months <sup>3</sup>   |
| <b>Haemophilus</b>  | 6 weeks                       | 4 weeks                               | 4 weeks <sup>4</sup>                       | 8 weeks (as final       |                         |

| <b>Catch-up Schedule for Persons Aged 4 Months to 6 Years</b> |                               |  |   |  |                         |
|---|-------------------------------|--|---|--|-------------------------|
| <b>Vaccine</b>  | <b>Minimum age for Dose 1</b> | <b>Minimum Interval between Doses</b>  |   |  |                         |
|   |                               | <b>Dose 1 to Dose 2</b>  | <b>Dose 2 to Dose 3</b>   | <b>Dose 3 to Dose 4</b>  | <b>Dose 4 to Dose 5</b> |
| <b><i>influenzae type b</i><sup>4</sup></b>                   |                               | if first dose given at age <12 months<br><br>8 weeks (as final dose) if first dose given at age 12 to 14 months<br><br>No further doses needed if first dose given at age ≥15 months   | if current age <12 months<br><br>8 weeks (as final dose) <sup>4</sup> if current age ≥12 months and second dose given at age <15 months<br><br>No further doses needed if previous dose given at age ≥15 months | dose)<br>This dose only necessary for children aged 12 months to 5 years who received 3 doses before age 12 months                   |                         |
| <b>Pneumococcal<sup>5</sup></b>                               | 6 weeks                       | 4 weeks if first dose given at age <12 months and current age <24 months<br><br>8 weeks (as final dose) if first dose given at age ≥12 months or current age 24 to 59 months<br><br>No further doses needed for healthy children if first dose given at age ≥24 months | 4 weeks if current age <12 months<br><br>8 weeks (as final dose) if current age ≥12 months<br><br>No further doses needed for healthy children if previous dose given at age ≥24 months                         | 8 weeks (as final dose)<br>This dose only necessary for children aged 12 months to 5 years who received 3 doses before age 12 months |                         |
| <b>Inactivated Poliovirus<sup>6</sup></b>                     | 6 weeks                       | 4 weeks  | 4 weeks   | 4 weeks <sup>6</sup>   |                         |
| <b>Measles,</b>   | 12 months                     | 4 weeks  |   |  |                         |

| Catch-up Schedule for Persons Aged 4 Months to 6 Years |                        |                                |                  |                  |                  |
|--|------------------------|--------------------------------|------------------|------------------|------------------|
| Vaccine  | Minimum age for Dose 1 | Minimum Interval between Doses |                  |                  |                  |
|  |                        | Dose 1 to Dose 2               | Dose 2 to Dose 3 | Dose 3 to Dose 4 | Dose 4 to Dose 5 |
| Mumps, Rubella <sup>7</sup>                            |                        |                                |                  |                  |                  |
| Varicella <sup>8</sup>                                 | 12 months              | 3 months                       |                  |                  |                  |
| Hepatitis A <sup>9</sup>                               | 12 months              | 6 months                       |                  |                  |                  |

| Catch-up Schedule for Persons Aged 7 to 18 Years                 |                        |   |   |  |                  |
|--|------------------------|---|---|--|------------------|
| Vaccine  | Minimum age for Dose 1 | Minimum Interval between Doses  |   |  |                  |
|  |                        | Dose 1 to Dose 2  | Dose 2 to Dose 3  | Dose 3 to Dose 4                               | Dose 4 to Dose 5 |
| Tetanus, Diphtheria/Tetanus, Diphtheria, Pertussis <sup>10</sup> | 7 years <sup>10</sup>  | 4 weeks   | 8 weeks if first dose given at age <12 months<br><br>6 months if first dose given at age ≥12 months | 6 months if first dose given at age <12 months |                  |
| Human Papillomavirus <sup>11</sup>                               | 9 years                | 4 weeks   | 12 weeks  |  |                  |
| Hepatitis A <sup>9</sup>   | 12 months              | 6 months  |   |  |                  |
| Hepatitis B <sup>1</sup>   | Birth                  | 4 weeks   | 8 weeks (and 16 weeks after first dose)   |  |                  |
| Inactivated Poliovirus <sup>6</sup>                              | 6 weeks                | 4 weeks   | 4 weeks   | 4 weeks <sup>6</sup>                           |                  |
| Measles, Mumps, Rubella <sup>7</sup>                             | 12 months              | 4 weeks   |   |  |                  |
| Varicella <sup>8</sup>   | 12 months              | 4 weeks if first dose given at age ≥13 years<br><br>3 months if first dose given at age <13 years |   |  |                  |

1. **Hepatitis B vaccine (HepB).** (Minimum age: birth)

- Administer the 3-dose series to those who were not previously vaccinated.
  - A 2-dose series of Recombivax HB® is licensed for 11 to 15 year olds.
2. **Rotavirus vaccine (Rota).** *(Minimum age: 6 weeks)*
    - Do not start the series later than age 12 weeks.
    - Administer the final dose in the series by 32 weeks of age. Do not administer a dose later than age 32 weeks.
    - Data on safety and efficacy outside of these age ranges are insufficient.
  3. **Diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP).** *(Minimum age: 6 weeks)*
    - The fifth dose is not necessary if the fourth dose was administered at age  $\geq 4$  years.
    - DTaP is not indicated for persons aged  $\geq 7$  years.
  4. **Haemophilus influenzae type b conjugate vaccine (Hib).** *(Minimum age: 6 weeks)*
    - Vaccine is not generally recommended for children aged  $\geq 5$  years.
    - If current age  $< 12$  months and the first 2 doses were PRP-OMP (PedvaxHIB® or ComVax® [Merck]), the third (and final) dose should be administered at age 12 to 15 months and at least 8 weeks after the second dose.
    - If first dose given at age 7 to 11 months, give 2 doses separated by 4 weeks plus a booster at age 12 to 15 months.
  5. **Pneumococcal conjugate vaccine (PCV).** *(Minimum age: 6 weeks)*
    - Vaccine is not generally recommended for children aged  $\geq 5$  years.
  6. **Inactivated poliovirus vaccine (IPV).** *(Minimum age: 6 weeks)*
    - For children who received an all-IPV or all-oral poliovirus (OPV) series, a fourth dose is not necessary if third dose was administered at age  $\geq 4$  years.
    - If both OPV and IPV were administered as part of a series, a total of 4 doses should be given, regardless of the child's current age.
  7. **Measles, mumps, and rubella vaccine (MMR).** *(Minimum age: 12 months)*
    - The second dose of MMR is recommended routinely at age 4 to 6 years but may be administered earlier if desired.
    - If not previously vaccinated, administer 2 doses of MMR during any visit with  $\geq 4$  weeks between the doses.
  8. **Varicella vaccine.** *(Minimum age: 12 months)*
    - The second dose of varicella vaccine is recommended routinely at age 4 to 6 years but may be administered earlier if desired.
    - Do not repeat the second dose in persons aged  $< 13$  years, if administered  $\geq 28$  days following the first dose.
  9. **Hepatitis A vaccine (HepA).** *(Minimum age: 12 months)*

- HepA is recommended for certain groups of children including in areas where vaccination programs target older children. See *MMWR* 2006;55(RR-7):1-23.

**10. Tetanus and diphtheria toxoids vaccine (Td) and tetanus and diphtheria toxoids and acellular pertussis vaccine (Tdap).** (*Minimum ages: 7 years for Td, 10 years for BOOSTRIX®, and 11 years for ADACEL™*)

- Tdap should be substituted for a single dose of Td in the primary catch-up series or as a booster if age-appropriate; use Td for other doses.
- A five-year interval from the last Td dose is encouraged when Tdap is used as a booster dose. A booster (4th) dose is needed if any of the previous doses were administered at age <12 months. Refer to ACIP recommendations for further information. See *MMWR* 2006;55(RR-3).

**11. Human papillomavirus vaccine (HPV).** (*Minimum age: 9 years*)

- Administer the HPV vaccine series to females at age 13 to 18 years if not previously vaccinated.

**CLINICAL ALGORITHM(S)**

None provided

**EVIDENCE SUPPORTING THE RECOMMENDATIONS**

**TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS**

The type of supporting evidence is not specifically stated for each recommendation.

**BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS**

**POTENTIAL BENEFITS**

- Effective and age-appropriate administration of vaccines to children and adolescents
- Decline in vaccine-preventable diseases among children and adolescents

**POTENTIAL HARMS**

Adverse reactions to vaccines

**QUALIFYING STATEMENTS**

**QUALIFYING STATEMENTS**

Additional vaccines may be licensed and recommended during the year. Licensed combination vaccines may be used whenever any components of the combination are indicated and other components of the vaccine are not contraindicated and if

approved by the U.S. Food and Drug Administration (FDA). Providers should consult the respective Advisory Committee on Immunization Practices (ACIP) statements for detailed recommendations.

## IMPLEMENTATION OF THE GUIDELINE

### DESCRIPTION OF IMPLEMENTATION STRATEGY

An implementation strategy was not provided.

## INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT CATEGORIES

### IOM CARE NEED

Staying Healthy

### IOM DOMAIN

Effectiveness

## IDENTIFYING INFORMATION AND AVAILABILITY

### BIBLIOGRAPHIC SOURCE(S)

American Academy of Pediatrics Committee on Infectious Diseases. Recommended immunization schedules for children and adolescents--United States, 2007. *Pediatrics* 2007 Jan;119(1):207-8, 3 p following 208. [2 references] [PubMed](#)

Centers for Disease Control and Prevention. Recommended immunization schedules for persons aged 0-18 years - United States, 2007. *MMWR Recomm Rep* 2007 Jan 5;55(51-52):Q1-4. [6 references]

### ADAPTATION

Not applicable: The guideline was not adapted from another source.

### DATE RELEASED

2004 Apr 30 (revised 2007 Jan)

### GUIDELINE DEVELOPER(S)

American Academy of Family Physicians - Medical Specialty Society  
American Academy of Pediatrics - Medical Specialty Society  
Centers for Disease Control and Prevention - Federal Government Agency [U.S.]

### SOURCE(S) OF FUNDING

United States Government

## **GUIDELINE COMMITTEE**

Committee on Infectious Diseases

## **COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE**

*Committee on Infectious Diseases, 2006 to 2007:* Joseph A. Bocchini Jr, MD, *Chairperson*; Robert S. Baltimore, MD; Henry H. Bernstein, DO; John S. Bradley, MD; Michael T. Brady, MD; Penelope H. Dennehy, MD; Margaret C. Fisher, MD; Robert W. Freneck Jr, MD; David W. Kimberlin, MD; Sarah S. Long, MD; Julia A. McMillan, MD; Lorry G. Rubin, MD

*Liaisons:* Richard D. Clover, MD, American Academy of Family Physicians; Marc A. Fischer, MD, Centers for Disease Control and Prevention; Richard L. Gorman, MD, National Institutes of Health; Douglas R. Pratt, MD, Food and Drug Administration; Anne Schuchat, MD, Centers for Disease Control and Prevention; Benjamin Schwartz, MD, National Vaccine Program Office; Jeffrey R. Starke, MD, American Thoracic Society; Jack Swanson, MD, Practice Action Group

*Ex Officio:* Larry K. Pickering, MD, Red Book Editor

*Consultant:* Edgar O. Ledbetter, MD

*Staff:* Alison Siwek, MPH

## **FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST**

Not stated

## **GUIDELINE STATUS**

This is the current release of the guideline.

This guideline updates previously published versions: American Academy of Pediatrics, Committee on Infectious Disease. Recommended childhood and adolescent immunization schedule--United States, 2006. *Pediatrics* 2006 Jan;117(1):239-40.

Centers for Disease Control and Prevention (CDC). Recommended childhood and adolescent immunization schedule -- United States, 2006. *MMWR Morb Mortal Wkly Rep* 2006 Jan 6;54(51&52):Q1-4.

## **GUIDELINE AVAILABILITY**

Electronic copies: Available from the [Centers for Disease Control and Prevention \(CDC\) Web site](#) and the [American Academy of Pediatrics \(AAP\) Policy Web site](#).

Print copies: Available from the Centers for Disease Control and Prevention, MMWR, Atlanta, GA 30333. Additional copies can be purchased from the Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402-9325; (202) 783-3238.

## **AVAILABILITY OF COMPANION DOCUMENTS**

None available

## **PATIENT RESOURCES**

None available

## **NGC STATUS**

This NGC summary was completed by ECRI on February 25, 2004. This summary was updated by ECRI on October 20, 2004 after the Centers for Disease Control and Prevention (CDC) issued interim recommendations in response to the shortage of influenza vaccine. This summary was updated again by ECRI on January 27, 2005, and on January 19, 2006. This summary was updated by ECRI on October 25, 2006 following the updated FDA advisory on Menactra (Meningococcal Conjugate Vaccine). This summary was updated again by ECRI on January 26, 2007. This summary was updated by ECRI on February 19, 2007 following the FDA advisory on Rotavirus, Live, Oral, Pentavalent vaccine (RotaTeq). This summary was updated by ECRI Institute on July 9, 2007 following the FDA advisory on RotaTeq (Rotavirus, Live, Oral, Pentavalent) vaccine.

## **COPYRIGHT STATEMENT**

No copyright restrictions apply.

## **DISCLAIMER**

### **NGC DISCLAIMER**

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at <http://www.guideline.gov/about/inclusion.aspx>.

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and

related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.

© 1998-2008 National Guideline Clearinghouse

Date Modified: 9/22/2008

